Revolution Medicines Presents Exploratory Subgroup Analyses From Phase 3 RASolute 302 Trial, As Late-Breaking Abstract At ESMO Congress 2026
Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival benefit compared with
Revolution Medicines shared new breakdowns of their cancer drug trial results. This deeper look helps doctors see which patients benefited most from treatment.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.